Wyeth withdraws EU filing for antidepressant
This article was originally published in Scrip
Executive Summary
Wyethhas withdrawn its European application for its SNRI Ellefore (desvenlafaxine), for the treatment of major depressive disorder (MDD) after the CHMPquestioned the drug's efficacy, the company said.